90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Lodermeyer, Veronika ^a   Suhr, Kristina ^a,c   Schrott, Nicola ^a   Kolbe, Christian ^a   Stürzel, Christina M ^a   Krnavek, Daniela ^a   Münch, Jan ^a   Dietz, Christian ^b   Waldmann, Tanja ^b   Kirchhoff, Frank ^a   Goffinet, Christine ^a,c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Antiviral factor; Env incorporation; HIV 1; Interferon

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; NEF PROTEIN; PROTEIN 90K; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VPU PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; NONHUMAN; PROGENY; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TARGET CELL; VIRUS IDENTIFICATION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; MURINAE;

ANTIGENS, NEOPLASM; CARRIER PROTEINS; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCOPROTEINS; HIV-1; HUMANS; INTERFERONS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR MARKERS, BIOLOGICAL; VIRUS ASSEMBLY; VIRUS RELEASE;

EID: 84885998675     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-111     Document Type: Article

References (49)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650. 10.1038/nature00939, 12167863.
2. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425-430. 10.1038/nature06553, 18200009.
3. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3(4):245-252. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
4. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474(7353):658-661. 10.1038/nature10195, 3179858, 21720370.
5. Laguette N, Bregnard C, Benichou S, Basmaciogullari S. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. Mol Aspects Med 2010, 31(5):418-433. 10.1016/j.mam.2010.05.003, 20594957.
6. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med 2012, 18(11):1682-1687. 10.1038/nm.2964, 22972397.
7. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med 2012, 2(5):a006940. 10.1101/cshperspect.a006940, 3331687, 22553496.
8. Audige A, Urosevic M, Schlaepfer E, Walker R, Powell D, Hallenberger S, Joller H, Simon HU, Dummer R, Speck RF. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. J Immunol 2006, 177(9):6227-6237.
9. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Gunthard HF, Goldstein DB, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010, 6(2):e1000781. 10.1371/journal.ppat.1000781, 2829051, 20195503.
10. Brakebusch C, Sures I, Jallal B, Mossie K, Fusco O, Iacobelli S, Ullrich A. Isolation and functional characterization of the human 90K promoter. Genomics 1999, 57(2):268-278. 10.1006/geno.1999.5760, 10198166.
11. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994, 269(28):18401-18407.
12. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131(6):1887-1898. 10.1053/j.gastro.2006.09.052, 17087946.
13. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010, 5(3):e9753. 10.1371/journal.pone.0009753, 2842296, 20339534.
14. Iacobelli S, Scambia G, Natoli C, Panici PB, Baiocchi G, Perrone L, Mancuso S. Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumor-associated antigen in human breast cancer cells. Int J Cancer 1988, 42(2):182-184. 10.1002/ijc.2910420207, 3403063.
15. Marth C, Dreps A, Natoli C, Zeimet AG, Lang T, Widschwendter M, Daxenbichler G, Ullrich A, Iacobelli S. Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. Int J Cancer 1994, 59(6):808-813. 10.1002/ijc.2910590617, 7989123.
16. Natoli C, Garufi C, Tinari N, D'Egidio M, Lesti G, Gaspari LA, Visini R, Iacobelli S. Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br J Cancer 1993, 67(3):564-567. 10.1038/bjc.1993.103, 1968249, 8439505.
17. Briggs NC, Natoli C, Tinari N, D'Egidio M, Goedert JJ, Iacobelli S. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res Hum Retroviruses 1993, 9(9):811-816. 10.1089/aid.1993.9.811, 7504933.
18. Groschel B, Braner JJ, Funk M, Linde R, Doerr HW, Cinatl J, Iacobelli S. Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol 2000, 20(2):117-122. 10.1023/A:1006634530672, 10821463.
19. Iacobelli S, Natoli C, D'Egidio M, Tamburrini E, Antinori A, Ortona L. Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. J Infect Dis 1991, 164(4):819. 10.1093/infdis/164.4.819, 1894946.
20. Longo G, Natoli C, Rafanelli D, Tinari N, Morfini M, Rossi-Ferrini P, D'Ostilio N, Iacobelli S. Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol 1993, 85(1):207-209. 10.1111/j.1365-2141.1993.tb08674.x, 8251396.
21. Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G, Iacobelli S. 90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1993, 6(4):370-375.
22. Natoli C, Iacobelli S, Ghinelli F. Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis 1991, 164(3):616-617. 10.1093/infdis/164.3.616, 1869854.
23. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986, 46(6):3005-3010.
24. Linsley PS, Horn D, Marquardt H, Brown JP, Hellstrom I, Hellstrom KE, Ochs V, Tolentino E. Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry 1986, 25(10):2978-2986. 10.1021/bi00358a037, 3521724.
25. Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci 1994, 19(1):5-8. 10.1016/0968-0004(94)90165-1, 8140623.
26. Laferte S, Loh LC, Keeler V. Monoclonal antibodies specific for human tumor-associated antigen 90K/Mac-2 binding protein: tools to examine protein conformation and function. J Cell Biochem 2000, 77(4):540-559. 10.1002/(SICI)1097-4644(20000615)77:4<540::AID-JCB3>3.0.CO;2-I, 10771511.
27. D'Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S. 90K (Mac-2 BP) in human milk. Clin Exp Immunol 1996, 104(3):543-546. 10.1046/j.1365-2249.1996.40745.x, 2200461, 9099942.
28. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993, 268(19):14245-14249.
29. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996, 56(19):4530-4534.
30. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 2011, 410(4):582-608. 10.1016/j.jmb.2011.04.042, 3139147, 21762802.
31. Crooks ET, Tong T, Osawa K, Binley JM. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 2011, 85(12):5825-5839. 10.1128/JVI.00154-11, 3126298, 21471242.
32. Nachmias D, Sklan EH, Ehrlich M, Bacharach E. Human immunodeficiency virus type 1 envelope proteins traffic toward virion assembly sites via a TBC1D20/Rab1-regulated pathway. Retrovirology 2012, 9:7. 10.1186/1742-4690-9-7, 3283470, 22260459.
33. Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R, Engel J. Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem 2002, 277(18):15690-15696. 10.1074/jbc.M200386200, 11867635.
34. Trahey M, Weissman IL. Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Proc Natl Acad Sci USA 1999, 96(6):3006-3011. 10.1073/pnas.96.6.3006, 15885, 10077627.
35. Muller SA, Sasaki T, Bork P, Wolpensinger B, Schulthess T, Timpl R, Engel A, Engel J. Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J Mol Biol 1999, 291(4):801-813. 10.1006/jmbi.1999.2996, 10452890.
36. Bieniasz PD, Cullen BR. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol 2000, 74(21):9868-9877. 10.1128/JVI.74.21.9868-9877.2000, 102023, 11024113.
37. Goujon C, Malim MH. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 2010, 84(18):9254-9266. 10.1128/JVI.00854-10, 2937661, 20610724.
38. Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D, Meltzer MS, Gendelman HE. Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol 1992, 66(12):7543-7548. 240466, 1279206.
39. Dianzani F, Castilletti C, Gentile M, Gelderblom HR, Frezza F, Capobianchi MR. Effects of IFN alpha on late stages of HIV-1 replication cycle. Biochimie 1998, 80(8-9):745-754.
40. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu SL, et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2002, 76(6):2606-2616. 10.1128/JVI.76.6.2606-2616.2002, 135977, 11861826.
41. Wang P, Heitman J. The cyclophilins. Genome Biol 2005, 6(7):226. 10.1186/gb-2005-6-7-226, 1175980, 15998457.
42. Pelliccia P, Galli L, de Martino M, Chiarelli F, Verrotti A, Sabatino G, Fornarini B, Iacobelli S, Natoli C. Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. Aids 2000, 14(4):F41-F45. 10.1097/00002030-200003100-00002, 10770531.
43. Fornarini B, Iacobelli S, Tinari N, Natoli C, De Martino M, Sabatino G. Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections. Clin Exp Immunol 1999, 115(1):91-94. 10.1046/j.1365-2249.1999.00782.x, 1905198, 9933425.
44. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, Andoh A, Fujiyama Y, Kawasaki T. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem 2011, 286(25):22403-22413. 10.1074/jbc.M110.215301, 3121387, 21515679.
45. Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010, 6(5):e1000908. 10.1371/journal.ppat.1000908, 2877745, 20523901.
46. Goffinet C, Allespach I, Oberbremer L, Golden PL, Foster SA, Johns BA, Weatherhead JG, Novick SJ, Chiswell KE, Garvey EP, et al. Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. J Virol 2009, 83(15):7706-7717. 10.1128/JVI.00683-09, 2708607, 19458008.
47. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A, Specht A, Sauter D, Dobner T, Kirchhoff F. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 2010, 7:1. 10.1186/1742-4690-7-1, 2823648, 20078884.
48. Wildum S, Schindler M, Munch J, Kirchhoff F. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol 2006, 80(16):8047-8059. 10.1128/JVI.00252-06, 1563805, 16873261.
49. Habermann A, Krijnse-Locker J, Oberwinkler H, Eckhardt M, Homann S, Andrew A, Strebel K, Krausslich HG. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol 2010, 84(9):4646-4658. 10.1128/JVI.02421-09, 2863769, 20147389.